SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Diego García-Compeán, José Alberto González-González, Fernando Javier Lavalle-González, Emmanuel Irineo González-Moreno, Jesús Zacarías Villarreal-Pérez, Héctor J. Maldonado-Garza, Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy, Digestive Diseases and Sciences, 2016, 61, 2, 371

    CrossRef

  2. 2
    Suhag Patel, Raxitkumar Jinjuvadia, Ravi Patel, Suthat Liangpunsakul, Insulin Resistance is Associated With Significant Liver Fibrosis in Chronic Hepatitis C Patients, Journal of Clinical Gastroenterology, 2016, 50, 1, 80

    CrossRef

  3. 3
    Swetha Rudraiah, Xi Zhang, Li Wang, Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet?, Annual Review of Pharmacology and Toxicology, 2016, 56, 1, 605

    CrossRef

  4. 4
    Paola Dongiovanni, Raffaela Rametta, Marica Meroni, Luca Valenti, The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development – a potential therapeutic target?, Expert Review of Gastroenterology & Hepatology, 2016, 10, 2, 229

    CrossRef

  5. 5
    Elena Canavesi, Marianna Porzio, Massimiliano Ruscica, Raffaela Rametta, Chiara Macchi, Serena Pelusi, Anna Ludovica Fracanzani, Paola Dongiovanni, Silvia Fargion, Paolo Magni, Luca Valenti, Increased circulating adiponectin in males with chronic HCV hepatitis, European Journal of Internal Medicine, 2015, 26, 8, 635

    CrossRef

  6. You have free access to this content6
    Wael Abdel-Razek, Imam Waked, Optimal therapy in genotype 4 chronic hepatitis C: finally cured?, Liver International, 2015, 35,
  7. 7
    Ching-Sheng Hsu, Shih-Jer Hsu, Hans Hsienhong Lin, Tai-Chung Tseng, Chia-Chi Wang, Ding-Shinn Chen, Jia-Horng Kao, A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin, Journal of the Formosan Medical Association, 2014, 113, 10, 716

    CrossRef

  8. 8
    F.-K. F. Cheng, D. M. Torres, S. A. Harrison, Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy?, Journal of Viral Hepatitis, 2014, 21, 1
  9. 9
    Sobia Kanwal, Tariq Mahmood, Hepatitis C virus resistance to interferon therapy: an alarming situation, Open Life Sciences, 2014, 9, 12

    CrossRef

  10. 10
    Wael Abdel-Razek, Imam Waked, Optimal Management of HCV Genotype 4, Current Hepatology Reports, 2014, 13, 4, 286

    CrossRef

  11. 11
    André J Scheen, Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease, Expert Opinion on Drug Metabolism & Toxicology, 2014, 10, 6, 839

    CrossRef

  12. 12
    Imam Waked, Waheed Doss, Manal Hamdy El-Sayed, Chris Estes, Homie Razavi, Gamal Shiha, Ayman Yosry, Gamal Esmat, The current and future disease burden of chronic hepatitis C virus infection in Egypt, Arab Journal of Gastroenterology, 2014, 15, 2, 45

    CrossRef

  13. 13
    Srikanta Dash, Partha Chandra, Kurt Ramazan, Robert Garry, Luis Balart, Cancer-Causing Viruses and Their Inhibitors, 2014,

    CrossRef

  14. 14
    Zobair Younossi, Francesco Negro, Lawrence Serfaty, Stanislas Pol, Moises Diago, Stefan Zeuzem, Pietro Andreone, Eric J. Lawitz, Stuart Roberts, Roberto Focaccia, Graham R. Foster, Andrzej Horban, Isabelle Lonjon-Domanec, Bruce Coate, Ralph DeMasi, Gaston Picchio, James Witek, Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial, Hepatology, 2013, 58, 6
  15. You have free access to this content15
    Gamal Esmat, Mohamed El Kassas, Mohamed Hassany, Mohamed Esmat Gamil, Maisa El Raziky, How to optimize HCV therapy in genotype 4 patients, Liver International, 2013, 33,
  16. 16
    Ahmed El Ray, Tarik Asselah, Rami Moucari, Maged El Ghannam, Alaa A. Taha, Mohamed A. Saber, Maha Akl, Raafat Atta, Mohamed Shemis, Azza S. Radwan, Ayman Ghali, Valerie Paradis, Patrick Marcellin, Insulin resistance, European Journal of Gastroenterology & Hepatology, 2013, 1

    CrossRef

  17. 17
    Tatsuya Minami, Takahiro Kishikawa, Masaya Sato, Ryosuke Tateishi, Haruhiko Yoshida, Kazuhiko Koike, Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C, Journal of Gastroenterology, 2013, 48, 2, 254

    CrossRef

  18. 18
    Ludovico Abenavoli, Samir Rouabhia, Type 2 diabetes mellitus in chronic hepatitis C virus infection: risk factor or consequence?, Expert Review of Gastroenterology & Hepatology, 2013, 7, 4, 295

    CrossRef

  19. 19
    Luigi E Adinolfi, Rosa Zampino, Luciano Restivo, Amedeo Lonardo, Paola Loria, Emerging Therapeutic Options for Hepatitis C, 2013,

    CrossRef

  20. 20
    Stephen A. Harrison, Fayez M. Hamzeh, Jian Han, Prashant K. Pandya, Muhammed Y. Sheikh, John M. Vierling, Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin, Hepatology, 2012, 56, 2
  21. 21
    C. Cooper, Hepatitis C Treatment Highlights From the 2011 American Association for the Study of Liver Disease Meeting, Clinical Infectious Diseases, 2012, 55, 3, 418

    CrossRef

  22. 22
    Vincent Wai-Sun Wong, Hepatitis C virus infection and diabetes: Not a straightforward relationship, Journal of Gastroenterology and Hepatology, 2012, 27, 11
  23. 23
    Mohammed Eslam, Reyes Aparcero, Youssef I. Mousa, Lourdes Grande, Yehia Shaker, Ahmed Ali, José A. del Campo, Mahmoud A. Khattab, Manuel Romero-Gomez, Insulin Resistance Impairs Viral Dynamics Independently of Ethnicity or Genotypes, Journal of Clinical Gastroenterology, 2012, 46, 3, 228

    CrossRef

  24. 24
    Stephen A Harrison, Matthew J Lincoln, Katharine K Roberts, Insulin resistance in chronic hepatitis C: the search for effective drug treatment continues, Expert Review of Gastroenterology & Hepatology, 2012, 6, 4, 401

    CrossRef

  25. 25
    Munechika Enjoji, Motoyuki Kohjima, Kazuhiro Kotoh, Makoto Nakamuta, Metabolic Disorders and Steatosis in Patients with Chronic Hepatitis C: Metabolic Strategies for Antiviral Treatments, International Journal of Hepatology, 2012, 2012, 1

    CrossRef

  26. 26
    L. Y. Lee, C. Y.W. Tong, T. Wong, M. Wilkinson, New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials, International Journal of Clinical Practice, 2012, 66, 4
  27. 27
    Vasilios Papastergiou, Dimitrios Dimitroulopoulos, Lamprini Skorda, Philippos Lisgos, Ioannis Ketikoglou, Nikolaos Kostas, Stylianos Karatapanis, Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: Does ethnicity matter?, Journal of Medical Virology, 2012, 84, 8
  28. 28
    F. Negro, Steatosis and insulin resistance in response to treatment of chronic hepatitis C, Journal of Viral Hepatitis, 2012, 19,
  29. 29
    Jian-Wu Yu, Li-Jie Sun, Yong-Hua Zhao, Peng Kang, Bing-Zhu Yan, The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance, International Journal of Infectious Diseases, 2012, 16, 6, e436

    CrossRef

  30. 30
    Mahmoud Aboelneen Khattab, Mohammed Eslam, The Impact of Host Factors on Management of Hepatitis C Virus, Hepatitis Monthly, 2012, 12, 4, 235

    CrossRef

  31. 31
    Elisabetta Bugianesi, Federico Salamone, Francesco Negro, The interaction of metabolic factors with HCV infection: Does it matter?, Journal of Hepatology, 2012, 56, S56

    CrossRef

  32. 32
    Ludovico Abenavoli, Piero L Almasio, Chronic hepatitis C infection and insulin resistance: two best friends, Expert Review of Anti-infective Therapy, 2011, 9, 8, 555

    CrossRef

  33. 33
    Vincent Kaddai, Francesco Negro, Current understanding of insulin resistance in hepatitis C, Expert Review of Gastroenterology & Hepatology, 2011, 5, 4, 503

    CrossRef

  34. 34
    Margaret F. Bassendine, David A. Sheridan, Daniel J. Felmlee, Simon H. Bridge, Geoffrey L Toms, R. Dermot G. Neely, HCV and the hepatic lipid pathway as a potential treatment target, Journal of Hepatology, 2011, 55, 6, 1428

    CrossRef

  35. 35
    Chao-Hung Hung, Chuan-Mo Lee, Sheng-Nan Lu, Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications, Expert Review of Anti-infective Therapy, 2011, 9, 5, 525

    CrossRef

  36. 36
    Pierre Deltenre, Alexandre Louvet, Maud Lemoine, Abbas Mourad, Laetitia Fartoux, Christophe Moreno, Jean Henrion, Philippe Mathurin, Lawrence Serfaty, Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: A meta-analysis, Journal of Hepatology, 2011, 55, 6, 1187

    CrossRef

  37. 37
    Marie-Louise C. Vachon, Stephanie H. Factor, Andrea D. Branch, Maria-Isabel Fiel, Maribel Rodriguez-Torres, Norbert Bräu, Richard K. Sterling, Jihad Slim, Andrew H. Talal, Douglas T. Dieterich, Mark S. Sulkowski, Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients, Journal of Hepatology, 2011, 54, 1, 41

    CrossRef

  38. 38
    Mahmoud A. Khattab, Peter Ferenci, Stephanos J. Hadziyannis, Massimo Colombo, Michael P. Manns, Piero L. Almasio, Rafael Esteban, Ayman A. Abdo, Stephen A. Harrison, Nazir Ibrahim, Patrice Cacoub, Mohammed Eslam, Samuel S. Lee, Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel, Journal of Hepatology, 2011, 54, 6, 1250

    CrossRef

  39. 39
    Francesco Negro, Mechanisms of hepatitis C virus-related insulin resistance, Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 5, 358

    CrossRef

  40. 40
    Stephane Chevaliez, Tarik Asselah, Mechanisms of non-response to antiviral treatment in chronic hepatitis C, Clinics and Research in Hepatology and Gastroenterology, 2011, 35, S31

    CrossRef

  41. 41
    Luigi E Adinolfi, Luciano Restivo, Rosa Zampino, Amedeo Lonardo, Paola Loria, Metabolic alterations and chronic hepatitis C: treatment strategies, Expert Opinion on Pharmacotherapy, 2011, 12, 14, 2215

    CrossRef

  42. 42
    Michael Trauner, Emina Halilbasic, Nuclear Receptors as New Perspective for the Management of Liver Diseases, Gastroenterology, 2011, 140, 4, 1120

    CrossRef

  43. 43
    Venessa Pattullo, Mark W Douglas, Jacob George, Organelle dysfunction in hepatitis C virus-associated steatosis: anything to learn from nonalcoholic steatohepatitis?, Expert Review of Gastroenterology & Hepatology, 2011, 5, 2, 265

    CrossRef

  44. 44
    Luca Valenti, MariaGrazia Rumi, Enrico Galmozzi, Alessio Aghemo, Benedetta Del Menico, Stella De Nicola, Paola Dongiovanni, Marco Maggioni, Anna Ludovica Fracanzani, Raffaela Rametta, Massimo Colombo, Silvia Fargion, Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C, Hepatology, 2011, 53, 3
  45. 45
    Lisa Franceschini, Stefano Realdon, Moira Marcolongo, Silvia Mirandola, Gladis Bortoletto, Alfredo Alberti, Reciprocal interference between insulin and interferon-alpha signaling in hepatic cells: A vicious circle of clinical significance?, Hepatology, 2011, 54, 2
  46. 46
    Marie-Louise C. Vachon, Douglas T. Dieterich, The HIV/HCV-Coinfected Patient and New Treatment Options, Clinics in Liver Disease, 2011, 15, 3, 585

    CrossRef

  47. 47
    Zoe Raglow, Carly Thoma-Perry, Richard Gilroy, Yu-Jui Yvonne Wan, The interaction between HCV and nuclear receptor-mediated pathways, Pharmacology & Therapeutics, 2011, 132, 1, 30

    CrossRef

  48. 48
    Mahmoud Aboelneen Khattab, Mohammed Emad Abdel-fattah, Mohammed Eslam, Asharf Abdelaleem, Rabab Atef Abdelaleem, Mohammed Shatat, Ahmed Ali, Lamia Hamdy, Heba Tawfek, Hepatic Steatosis in Genotype 4 Chronic Hepatitis C Patients, Journal of Clinical Gastroenterology, 2010, 1

    CrossRef

  49. 49
    Tarik Asselah, Emilie Estrabaud, Ivan Bieche, Martine Lapalus, Simon De Muynck, Michel Vidaud, David Saadoun, Vassili Soumelis, Patrick Marcellin, Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin, Liver International, 2010, 30, 9
  50. 50
    Mahmoud Khattab, Mohammed Eslam, Mohammed Ahmed Sharwae, Mohammed Shatat, Ahmed Ali, Lamia Hamdy, Insulin Resistance Predicts Rapid Virologic Response to Peginterferon/Ribavirin Combination Therapy in Hepatitis C Genotype 4 Patients, The American Journal of Gastroenterology, 2010, 105, 9, 1970

    CrossRef

  51. 51
    Francesco Negro, Metabolic Factors and Steatosis in Patients with Hepatitis B and C,
  52. 52
    Venessa Pattullo, Jacob George, The Problem of Insulin Resistance and its Effect on Therapy,